AR053115A1 - Derivados de hidroxifenoles, procesos para su preparacion, composiciones farmaceuticas que los comprenden y sus usos terapeuticos - Google Patents

Derivados de hidroxifenoles, procesos para su preparacion, composiciones farmaceuticas que los comprenden y sus usos terapeuticos

Info

Publication number
AR053115A1
AR053115A1 ARP060100137A ARP060100137A AR053115A1 AR 053115 A1 AR053115 A1 AR 053115A1 AR P060100137 A ARP060100137 A AR P060100137A AR P060100137 A ARP060100137 A AR P060100137A AR 053115 A1 AR053115 A1 AR 053115A1
Authority
AR
Argentina
Prior art keywords
radical
optionally substituted
atom
alkyl
different
Prior art date
Application number
ARP060100137A
Other languages
English (en)
Inventor
Catherine Vidal
Nathalie Adje
Stephane Yvon
Jean Jacques Zeiller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR053115A1 publication Critical patent/AR053115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 1: Compuesto de la formula (1): en la que R1 representa -O-R1 o -NR'1R'' y R'1 y R''1 idénticos o diferentes, seleccionados de un átomo de hidrogeno, un radical alquilo, un radical alquenilo, un radical alquinilo, un radical cicloalquilo, un radical arilo y un radical heteroarilo; A representa un radical bivalente hidrocarbonado lineal o ramificado, saturado o insaturado que contiene de 1 a 10 átomos de carbono; R2 está seleccionado de: un radical alquilo, alquenilo o alquinilo; un radical cicloalquilalquilo opcionalmente sustituido; un radical arilalquilo opcionalmente sustituido; y un radical heterociclilalquilo opcionalmente sustituido; X está seleccionado de un átomo de oxígeno y un átomo de azufre; Y y Z, idénticos o diferentes, están seleccionados, de modo independiente entre si, de un átomo de hidrogeno, un átomo de halogeno, un radical alquilo y un radical -O-R3, -C(O)-R3, -C(O)-NHR3 o -C(O)-NR3R4; o bien Y y Z forman juntos, con los átomos de carbono que llevan, un anillo de 5 miembros que comprende una funcion cetona; y R3 y R4, idénticos o diferentes, están seleccionados de modo independiente entre sí, de un átomo de hidrogeno y un radical alquilo, o bien R3 y R4 forman juntos, con el átomo de nitrogeno que los lleva, un heterociclo opcionalmente sustituido; sus posibles isomeros opticos, formas oxidadas y solvatos, y también sus sales por adicion farmacéuticamente aceptables con ácidos o bases.
ARP060100137A 2005-01-14 2006-01-13 Derivados de hidroxifenoles, procesos para su preparacion, composiciones farmaceuticas que los comprenden y sus usos terapeuticos AR053115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0500420A FR2880887B1 (fr) 2005-01-14 2005-01-14 Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique

Publications (1)

Publication Number Publication Date
AR053115A1 true AR053115A1 (es) 2007-04-25

Family

ID=35033619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100137A AR053115A1 (es) 2005-01-14 2006-01-13 Derivados de hidroxifenoles, procesos para su preparacion, composiciones farmaceuticas que los comprenden y sus usos terapeuticos

Country Status (16)

Country Link
US (1) US8653134B2 (es)
EP (1) EP1836150B1 (es)
JP (1) JP2008526904A (es)
KR (1) KR20070092278A (es)
CN (1) CN101098846A (es)
AR (1) AR053115A1 (es)
AT (1) ATE481377T1 (es)
AU (1) AU2005324904B2 (es)
BR (1) BRPI0519855A2 (es)
CA (1) CA2594707C (es)
DE (1) DE602005023659D1 (es)
ES (1) ES2353149T3 (es)
FR (1) FR2880887B1 (es)
MX (1) MX2007008351A (es)
WO (1) WO2006074798A1 (es)
ZA (1) ZA200706706B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100877200B1 (ko) 2007-09-11 2009-01-07 주식회사 동희산업 가속페달 장치의 킥 다운 스위치
JP5960839B2 (ja) * 2012-11-15 2016-08-02 帝人株式会社 ６，６’−（エチレンジオキシ）ジ−２−ナフトエ酸ジエステルの製造方法
EP3943771B1 (en) 2020-07-21 2023-11-15 Siemens Aktiengesellschaft Method and apparatus of assembling one or more bearings

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
BE654557A (es) * 1963-07-13
US3378582A (en) * 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
FR1498459A (es) * 1965-07-30 1968-01-08
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
DE2208893A1 (de) * 1972-02-25 1973-08-30 Boehringer Mannheim Gmbh Tricyclische alpha-oxy-carbonsaeurederivate und verfahren zur herstellung derselben
JPS518228A (ja) * 1974-07-10 1976-01-23 Takeda Chemical Industries Ltd Chikanfuenokishikarubonsanruino seizoho
JPS527426A (en) * 1975-07-08 1977-01-20 Ube Ind Ltd Plant growth regulator
GB1559977A (en) * 1975-11-25 1980-01-30 Ici Ltd Amines
JPS5732288A (en) * 1980-07-14 1982-02-20 Clin Midy Tarampicillin 2-methoxyphenoxyacetate and manufacture
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
EP0525888A1 (en) * 1991-07-29 1993-02-03 Merck & Co. Inc. New catechol type non-steroidal drugs as 5-alpha reductase inhibitors
DE4142514A1 (de) * 1991-12-21 1993-06-24 Basf Ag Verfahren zur bekaempfung von pilzen
JPH07173143A (ja) * 1993-12-17 1995-07-11 Wakamoto Pharmaceut Co Ltd 新規２−チオキソ−４−チアゾリジノン誘導体及び医薬
WO1995022323A1 (en) * 1994-02-16 1995-08-24 Idun Pharmaceuticals Methods for controlling free radical generation by inflammatory cells
WO1998013347A1 (en) * 1996-09-26 1998-04-02 Novartis Ag Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
ATE427925T1 (de) * 1999-11-05 2009-04-15 Emisphere Tech Inc Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
KR20020081424A (ko) * 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
DE10142665B4 (de) * 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
EP1615698B1 (en) * 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
WO2004089416A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
JPWO2005012221A1 (ja) * 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
KR20060037442A (ko) * 2003-08-14 2006-05-03 화이자 인코포레이티드 Ｈｉｖ 감염 치료용 피페라진 유도체
WO2005035495A2 (en) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2005298437A (ja) * 2004-04-15 2005-10-27 Astellas Pharma Inc ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体
FR2869611B1 (fr) * 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20080255078A1 (en) * 2005-11-22 2008-10-16 Subba Reddy Katamreddy Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators
EP1951217A4 (en) * 2005-11-22 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS

Also Published As

Publication number Publication date
FR2880887A1 (fr) 2006-07-21
AU2005324904B2 (en) 2011-10-13
CA2594707A1 (en) 2006-07-20
AU2005324904A1 (en) 2006-07-20
WO2006074798A1 (en) 2006-07-20
EP1836150A1 (en) 2007-09-26
CA2594707C (en) 2013-10-22
MX2007008351A (es) 2007-07-25
KR20070092278A (ko) 2007-09-12
CN101098846A (zh) 2008-01-02
US8653134B2 (en) 2014-02-18
EP1836150B1 (en) 2010-09-15
ES2353149T3 (es) 2011-02-25
ATE481377T1 (de) 2010-10-15
FR2880887B1 (fr) 2009-01-30
JP2008526904A (ja) 2008-07-24
BRPI0519855A2 (pt) 2009-03-24
DE602005023659D1 (de) 2010-10-28
US20080161308A1 (en) 2008-07-03
ZA200706706B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
UY26727A1 (es) Derivados de tropano útiles en terapia
AR038047A1 (es) Agentes terapeuticos
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
NO20080391L (no) Pyrazolbaserte LXR modulatorer
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
AR034475A1 (es) Derivados de androstano antiinflamatorios
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR081573A1 (es) N-[(het)ariletil)]pirazo(tio)carboxamidas y sus analogos heterosustituidos y su uso como fungicidas
UY28369A1 (es) Agentes terapéuticos
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
HN2002000156A (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
ECSP088296A (es) Compuestos terapéuticos
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR067060A1 (es) Derivados de guanina policiclicos y sus metodos de uso
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure